US Stock MarketDetailed Quotes

AMGN Amgen

Watchlist

327.360
+2.500+0.77%

Close Mar 10 16:00 ET

328.020
+0.660+0.20%

Pre 07:08 ET

175.86BMarket Cap43.30P/E (TTM)

Amgen Stock Forum

Teddy123

Mar 8 09:01

AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

$Amgen (AMGN.US)$
Can This New Atopic Dermatitis Drug Challenge Current Market Leaders? Phase 3 Data Reveals Key Insights

10xStockPicks

Feb 21 07:57

Esperion Therapeutics On The Verge Of Being Acquired, Upside Could Be Over 500% In The Near Future

$Esperion Therapeutics (ESPR.US)$Esperion Therapeutics (ESPR): A High-Growth Opportunity with Potential 10x Returns
Esperion Therapeutics (ESPR), currently trading under $2 per share, has been attracting considerable attention from analysts. Recently, three analysts reaffirmed strong "Buy" ratings, with price targets ranging from $5 to $16 per share. Among the nine analysts covering Esperion, seven h...

Tao Lao Man Official

Feb 12 15:16

$Amgen (AMGN.US)$
AMGN, MRNA, PFE, JNJ ARE SAME BUS OR NOT = AMGN, MRNA, PFE, JNJ SEM BUT ZAY KO 🤔

Moomoo News Global

Feb 5 07:04

Columns Tariff Investment Opportunities: Four Sectors as Potential Safe Havens

Over the weekend, President Donald Trump announced tariffs on the U.S.'s top three trading partners—Canada, Mexico, and China—and threatened similar measures against the EU. On Monday, U.S. stocks experienced a selloff, with the major indices dropping. Losses narrowed, however, after news broke of a delay in imposing tariffs on Mexico.
Market worries over the tariffs focus on two key issues. U.S. companies that depend heavily ...

Stock_Drift

Feb 4 15:42

Amgen Q4 revenue up 11%, at $9.1B

$Amgen (AMGN.US)$

10xStockPicks

Jan 23 07:47

Today 3 Analysts Place BUY Ratings On This $2 Stock $7,$9 & $16 Which Is An Acquisition Target by BIG Pharma

$Esperion Therapeutics (ESPR.US)$ Jan 23, 2025 Three analysts are bullish on Esperion Therapeutics with price targets on this $2 stock ranging from $7 to $16 a share.
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...

Stock_Drift

Jan 18 08:51

$GlaxoSmithKline (GSK.US)$ $Amgen (AMGN.US)$ $AstraZeneca (AZN.US)$

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

vampirekitty169

Dec 31, 2024 09:05

🚀🚀🚀

$Amgen (AMGN.US)$ Bought as soon as I got the news and it’s +3% within 10 minutes, looking good!

What's new: Latest stock news and analysis

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15, 2024 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...